top of page
Videos
1 June 2023
Inside the KappaMab manufacturing process
26 May 2023
Karen Wilde, myeloma patient story - Short Video
26 May 2023
Karen Wilde, myeloma patient story - Long Video
3 May 2023
Our value inflection points between Q2 2023 and FY 2024
3 May 2023
The competitive advantage of our immunotherapies explained
3 May 2023
Meet our team - An introduction to Dr Geoffrey Nichol
22 December 2022
The latest on our CAR-T technology and more, presented at Myeloma Australia’s 4th National Myeloma Workshop
21 December 2022
Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma
15 December 2022
What makes our immunotherapies different on the large and growing multiple myeloma treatment market
13 October 2022
HaemaLogiX company overview with CEO Bryce Carmine - October, 2022
15 August 2022
Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process
15 March 2022
HaemaLogiX's Mary Sartor's presentation to the 63rd Annual ASH Annual Meeting in Atlanta, Georgia 2021
16 February 2022
How KappaMab works. KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.
bottom of page